Your session is about to expire
← Back to Search
Targeted Therapy for Salivary Gland Cancer
Study Summary
This trial is studying if certain drugs can help treat salivary gland cancer. In the first phase, doctors will see what kind of cancer the patient has. In the second phase, the patient will receive a matched treatment if their cancer has a specific aberration. If not, the patient will receive Selinexor.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 2 trial • 116 Patients • NCT02025985Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My diagnosis of a salivary gland tumor was confirmed through testing.My cancer is getting worse as shown by tests or how I feel.My tumor does not have enough tissue for detailed genetic testing.I stopped my last treatment without my cancer getting worse.I have previously received the same drug that I will be assigned in phase 2.I can provide a sample of my tumor for testing.I can take pills and don't have bowel blockage or inflammatory bowel disease.I can take care of myself but might not be able to do heavy physical work.My cancer has come back or spread to other parts.My salivary gland cancer has returned or spread and cannot be cured.I have at least one tumor that can be measured.I am not taking any medications that can affect my heart's rhythm.My brain metastases are stable and not causing symptoms.I have no history of serious heart problems.I do not have any other active cancer.I am 18 years old or older.My blood, liver, kidneys, and heart are functioning well.I don't have any serious health issues that treatment could worsen.My doctor expects I have less than 3 months to live.I refuse to have my tumor tissue tested for genetic changes.My cancer can be measured by standard health scans.My cancer's genetic profile has been analyzed and results are available.
- Group 1: Matched Therapy
- Group 2: Unmatched Treatment (Selinexor)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research an unprecedented investigation?
"Selinexor has been studied since 2014, when it was first trialled by Karyopharm Therapeutics Inc. Following this initial 16 person trial in which the drug passed Phase 1 evaluation, there are now 48 active clinical trials for Selinexor being conducted all over the world from 28 different nations and 259 cities."
What is the total number of participants involved in this experiment?
"Indeed, the available information on clinicaltrials.gov highlights that this medical trial is enlisting patients as of now. It was initially posted in June 2014 and was refreshed most recently on September 19th 2022. The research requires 200 individuals to be enrolled from one site."
Has Selinexor been tested in other clinical research studies?
"Currently, 48 studies are being conducted on Selinexor. Of these trials, 4 have progressed to Phase 3 clinicals. The majority of this research is located in Bethesda, Maryland; however 924 other sites across the country are running tests for this potential treatment."
Are there any opportunities to participate in this research trial currently?
"Per the information found on clinicaltrials.gov, this medical trial is currently recruiting candidates. It was originally posted online in June of 2014 and has seen its most recent update take place in September of 2022."
Share this study with friends
Copy Link
Messenger